Rexulti - Otsuka Pharmaceutical Co., Ltd.

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Home Otsuka US

Generic Product News: May 2023

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

REXULTI Drug Insight and Market Forecast - 2032

Otsuka Pharmaceutical Establishes Subsidiary in Singapore｜News Releases

REXULTI® (brexpiprazole) Patient Information Website

REXULTI BREXPIPRAZOLE - Otsuka Pharmaceutical Co., Inc. Trademark Registration

FDA Approves New Schizophrenia, Depression Drug Brexpiprazole - Psychiatry Advisor

Otsuka America Pharmaceutical 59148003613 - McKesson Medical-Surgical

Rexulti (Brexpiprazole) - PSYCH-MENTAL HEALTH HUB